## **Provider update**







## **Quality Measures Desktop Reference for Medicaid Providers**

Please note: The information provided is based on HEDIS® Measurement year 2020 and 2021 technical specifications and is subject to change based on guidance given by the National Committee for Quality Assurance, CMS and state recommendations. Please refer to the appropriate agency for additional guidance.

The \*measures include telehealth accommodations.

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Adults	Adults' Access to Preventive/ Ambulatory Health Services (AAP)	HEDIS	Ages 20 and older	Annual	Members who had an ambulatory or preventive care visit during the year
	*Plan All-Cause Readmissions (PCR)	HEDIS	Ages 18 and older	Annual	The number of acute inpatient and observation stays during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission
	Flu Vaccinations for Adults Ages 18 to 64 (FVA)	CAHPS®	Ages 18 to 64	Annual	Members vaccinated for influenza between July 1st and December 31st
	Medical Assistance With Smoking and Tobacco Use Cessation (MSC)	CAHPS	Ages 18 and older	Annual	Members who are current tobacco users who received the following from a provider during the year:  Cessation advice  Recommendation for or discussion of cessation medications  Recommendation for or discussion of cessation methods or strategies
	Use of Imaging Studies for Low Back Pain (LBP)	HEDIS	Ages 18 to 50	Annual	Members who had a primary diagnosis of lower back pain and <b>did not</b> have an imaging study (e.g., plain X-ray, MRI or CT scan) within 28 days of the diagnosis

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Adults	Appropriate Treatment for Upper Respiratory Infection (URI)	HEDIS	Ages 3 months and older	Annual	Members with a diagnosis of URI who <b>did not</b> receive an antibiotic prescription
	*Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)	HEDIS	Ages 13 and older	Annual	<ul> <li>Members with a new episode of alcohol or other drug (AOD) abuse or dependence who received:</li> <li>Initiation of AOD treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth or medication treatment within 14 days of diagnosis</li> <li>Engagement of AOD treatment and who were engaged in ongoing AOD treatment within 34 days of the initiation visit.</li> </ul>
	Frequency of Selected Procedures (FSP)	HEDIS	Not specified	Annual	This measure summarizes the utilization of frequently performed procedures that often show wide regional variation and have generated concern regarding potentially inappropriate utilization.
	Ambulatory Care (AMB)	HEDIS	Not specified	Annual	This measure summarizes utilization of ambulatory care in the following categories:  Outpatient Visits including telehealth.  ED Visits.
	Appropriate Testing for Pharyngitis (CWP)	HEDIS	Ages 3 and older	Annual	Members who have been diagnosed with pharyngitis, dispensed an antibiotic <b>and</b> received group A streptococcus (strep) test for the episode
Females	*Prenatal and Postpartum Care (PPC)	HEDIS	Live birth	Annual	The percentage of deliveries of live births on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. This measure assesses the following facets of prenatal and postpartum care:  • Members who had a prenatal visit within the first trimester or within 42 days of enrollment in the plan  • Members who had a postpartum visit on or between 7 and 84 days after delivery

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Females	*Breast Cancer Screening (BCS)	HEDIS	Ages 50 to 74	Every two years	Members who had a mammogram screening during the year or prior year
	Cervical Cancer Screening (CCS)	HEDIS	Ages 21 to 64	Varies by age	<ul> <li>The percentage of women 21 to 64 years of age who were screened for cervical cancer using either of the following criteria:</li> <li>Women 21 to 64 years of age who had cervical cytology performed within the last three years</li> <li>Women 30 to 64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last five years</li> <li>Women 30 to 64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last five years</li> </ul>
	Non-Recommended Cervical Cancer Screening in Adoles cent Females (NCS)	HEDIS	Ages 16 to 20	Annual	Adoles cent females who were screened <b>unnecessarily</b> for cervical cancer <b>Note:</b> Per the recommendations of the CDC, cervical cancer screening should begin at age 21.
	Chlamydia Screening in Women (CHL)	HEDIS	Ages 16 to 24	Annual	Members who are sexually active <b>and</b> who had at least one screening test for chlamydia during the year
Children and adolescents	Immunizations for Adolescents (IMA)	HEDIS	Ages-13	Multiple doses	Members who had one dose of meningococcal vaccine (MenACWY or MenB), one tetanus, diphtheria toxoids and a cellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday.  Note: The CDC recommendations for HPV vaccine series is as follows:  2 shot series for 11- to 12-year-olds  3 shot series for those with weakened immune systems and for those who start the series at 15 years or older
	*Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents (WCC)	HEDIS	Ages 3 to 17	Annual	Members who had an outpatient visit with a PCP or OB/GYN during the year in which the following were documented:  Height, weight and BMI percentile  Counseling for nutrition  Counseling for physical activity with recommendations and not solely for safety

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Children and adolescents	Childhood Immunization Status (CIS)	HEDIS	Ages 0 to 2	Multiple doses	Members who had appropriate doses of the following vaccines by their 2nd birthday: four — diphtheria, tetanus and a cellular pertussis (DTaP), three — polio (IPV), one — measles, mumps and rubella (MMR), three — haemophilus influenza type B (HiB), three — hepatitis B (Hep B), one — chicken pox (VZV), four — pneumococcal conjugate (PCV), one — hepatitis A (Hep A), two or three — Rotavirus (RV), and two — influenza (Flu) by their 2nd birthday
	Early and Periodic Screening, Diagnosis and Treatment (EPSDT) program	EPSDT	Ages 0 to 20	Multiple	<ul> <li>Screening must include:</li> <li>Comprehensive health development history (inclusive both physical and mental health).</li> <li>Comprehensive unclothed physical exam.</li> <li>Appropriate immunizations.</li> <li>Laboratory tests.</li> <li>Lead toxicity screening.</li> <li>Health education including anticipatory guidance.</li> <li>Vision services.</li> <li>Dental services.</li> <li>Hearing services.</li> <li>Other necessary health care — diagnostic services and treatment to correct or ameliorate defects, physical and mental illnesses, and conditions discovered by the screening services.</li> </ul>
	Lead Screening in Children (LSC)	HEDIS	Ages 0 to 2	Once before age 2	Members who had one or more capillary or venous lead blood test by their 2nd birthday
	Annual Dental Visit (ADV)	HEDIS	Ages 2 to 20	Annual	Members who had at least one dental visit during the year
	*Well-Child Visits in the First 30 Months of Life <b>(W30)</b>	HEDIS	Ages 0 to 15 months Ages 15-30 months	6 visits 2 visits	<ul> <li>Members who had the following number of well-child visits with a PCP during the last 15 months. The following rates are reported:</li> <li>Well-Child Visits in the First 15 Months. Children who turned 15 months old during the measurement year: Six or more well-child visits.</li> <li>Well-Child Visits for Age 15 Months-30 Months. Children who</li> </ul>
					turned 30 months old during the measurement year: Two or more well-child visits.

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Children and adolescents	*Child and Adolescent Well-Care Visits (WCV)	HEDIS	Ages 3 to 21	Annual	Members who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year. Note: Visit the Bright Futures website for more information about well-child visits (https://brightfutures.aap.org/materials-and-tools/guidelines-and-pocket-guide/).
Cardiovascular conditions	*Controlling High Blood Pressure (CBP)	HEDIS	Ages 18 to 85	Annual	Members 18 to 85 years of age who had a diagnosis of HTN <b>and</b> whose blood pressure (BP) was a dequately controlled (< 140/90 mm Hg) during the measurement year.  Note: If no BP is recorded during the measurement year, assume that the member is <i>not controlled</i> .
	*Persistence of Beta-Blocker Treatment After a Heart Attack ( <b>PBH</b> )	HEDIS	Ages 18 and older	After discharge	Members with an inpatient discharge for acute myocardial infarction (AMI) <b>and</b> who received beta-blocker treatment for six months after a hospital discharge for AMI
	*Statin Therapy for Patients With Cardiovascular Disease (SPC)	HEDIS	Men ages 21 to 75 Women ages 40 to 75	Annual	Members with a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria:  Received Statin Therapy: Members who were dispensed at least one high- or moderate-intensity statin medication  Statin Adherence 80%: Members who remained on a high- or moderate-intensity statin medication for at least 80% of the time from prescription start to end of the year

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Cardiovascular conditions	Cardiac Rehabilitation (CRE) (Note: First year Measure for 2020)	HEDIS	Ages 18 and older	Annual	<ul> <li>Members who have attended cardiac rehabilitation following a qualified cardiac event including, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement.</li> <li>Four rates are reported:         <ul> <li>Initiation. The percentage of members who attended 2 or more sessions of cardiac rehabilitation within 30 days after a qualifying event.</li> <li>Engagement 1. The percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event.</li> <li>Engagement 2. The percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.</li> <li>Achievement. The percentage of members who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.</li> </ul> </li> </ul>
Diabetes	*Comprehensive Diabetes Care (CDC)	HEDIS	Ages 18 to 75  Ages 18 to 85	Annual	The percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had each of the following:  Hemoglobin A1c (HbA1c) testing  HbA1c poor control (>9%)  HbA1c control (<8%)  Eye exam (retinal) performed  BP control (<140/90 mm Hg)  Members with diabetes (type 1 and type 2) who received a kidney
	Evaluation for Patients With Diabetes (KED) (Note: First Year measure for 2020)				health evaluation, defined by an estimated glomerular filtration rate (eGFR) <i>and</i> a urine albumin-creatinine ratio (uACR), during the measurement year.

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Diabetes	*Statin Therapy for Patients With Diabetes (SPD)	HEDIS	Ages 40 to 75	Annual	Members with a diagnosis of diabetes who do not have atheros clerotic cardiovascular disease  Received Statin Therapy: Members who were dispensed at least one statin medication of any intensity during the measurement year  Statin Adherence 80%: Members who remained on a statin medication of any intensity for at least 80% of the treatment period
Respiratory conditions	*Asthma Medication Ratio (AMR)	HEDIS	Ages 5 to 64	Annual	Members who have persistent asthma <b>and</b> had a ratio of controller medications to total asthma medications of 0.50 or greater
	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchi olitis (AAB)	HEDIS	Ages 3 months and older	Annual	Members who <b>did not</b> receive an antibiotic prescription <b>after</b> a diagnosis of acute bronchitis/bronchiolitis
	Pharmacotherapy Management of COPD Exacerbation (PCE)	HEDIS	Ages 40 and older	Inpatient discharge or ED event	Members who had an acute inpatient discharge or emergency department (ED) visit for chronic obstructive pulmonary disease (COPD) exacerbation and who were dispensed appropriate medications:  Systemic corticosteroid (or there was evidence of an active prescription) within 14 days of the event  Bronchodilator(or there was evidence of an active prescription) within 30 days of the event
	*Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	HEDIS	Ages 40 and older	As newly diagnosed/ newly active	Members who had a <b>new</b> diagnosis of COPD or <b>newly</b> active COPD who received spirometry testing to confirm the COPD diagnosis

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Behavioral health	*Follow-Up Care for Children Prescribed ADHD Medication (ADD)	HEDIS	Ages 6 to 12	Varies by phase	Members who were <b>newly</b> prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed — Two rates are reported:  • Initiation phase: follow-up visit with prescriber within 30 days of prescription  • Continuation and maintenance phase: remained on medication for at least 210 days and had two more additional visits within nine months (270 days) after the end of the initiation phase
	*Antidepressant Medication Management (AMM)	HEDIS	Ages 18 and older	Per episode	Members who were treated with antidepressant medication, had a diagnosis of major depression <b>and</b> who remained on an antidepressant medication treatment for:  • Effective Acute Phase: At least 84 days (12 weeks)  • Effective Continuation Phase: At least 180 days (6 months)
	*Follow-Up After Hos pitalization for Mental Illness ( <b>FUH)</b>	HEDIS	Ages 6 and older	Withinseven and/or 30 days after discharge	Members who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses, and who had a follow-up visit with a mental health practitioner — Two rates are reported:  The percentage of discharges for which the member received follow-up within 30 days after discharge.  The percentage of discharges for which the member received
	*Follow-Up After High Intensity Care for Substance Use Disorder <b>(FUI)</b>	HEDIS	Ages 13 and older	Within seven and/or 30 days after discharge	follow-up within 7 days after discharge.  Members of a cute inpatient hospitalizations, residential treatment or detoxification visits for a diagnosis of substance use that result in a follow-up visit or service for substance use disorder — Two rates are reported:  The percentage of visits or discharges for which the member received follow-up for substance use disorder within the 30 days after the visit or discharge  The percentage of visits or discharges for which the member received follow-up for substance use disorder within the seven days after the visit or discharge

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Behavioral health	*Follow-Up After Emergency Department Visit for Mental Illness (FUM)	HEDIS	Ages 6 and older	Withinseven and/or 30 days after ED visit	Members with a principal diagnosis of a mental illness, or intentional self-harm, who had a follow-up visit for mental illness:  Follow-up within 30 days of the ED visit (31 total days).  Follow-up within 7 days of the ED visit (8 total days).
	*Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA)	HEDIS	Ages 13 and older	Withinseven and/or 30 days after ED visit	Members with a principal diagnosis of alcohol and other drug (AOD) abuse or dependence, who had a follow-up visit for AOD:  • A follow-up visit 30 days of the ED visit (31 total days)  • A follow-up visit 7 days of the ED visit (8 total days)
	Pharmacotherapy for Opioid Use Disorder (POD)	HEDIS	Ages 16 and older	Annual	Members with a diagnosis of Opioid use disorder (OUD) with new OUD pharmacotherapy events with OUD pharmacotherapy for 180 or more days
	*Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	HEDIS	Ages 18 to 64	Annual	Members with schizophrenia, schizoaffective disorder or bipolar disorder <b>and who are not diabetic,</b> who had a glucose test or HbA1c during the year
	*Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	HEDIS	Ages 18 to 64	Annual	Members with schizophrenia or schizoaffective disorder and diabetes who had <b>both</b> an LDL-C and an HbA1c test during the year
	*Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	HEDIS	Ages 18 to 64	Annual	<ul> <li>Members with schizophrenia, schizoaffective disorder and cardiovascular disease who had an LDL-C test during the year</li> <li>Note: Indicators of cardiovascular disease include:         <ul> <li>Inpatient discharge for acute myocardial infarction (AMI) or coronary artery bypass grafting (CABG) during the year.</li> <li>Diagnosis of percutaneous coronary intervention (PCI) in any setting during the year.</li> <li>Diagnosis of ischemic vascular disease (IVD) during an inpatient or outpatient visit in both the current year and the prior year.</li> </ul> </li> </ul>

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Behavioral health	*Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	HEDIS	Ages 18 and older	Annual	Members with schizophrenia or schizoaffective disorder who were dispensed an antipsychotic medication <b>and</b> remained on the antipsychotic medication for at least 80% of the time between the of their treatment period.
	Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	HEDIS	Ages 1 to 17	Annual	Members who had two or more antipsychotic prescriptions who had metabolic testing during the year. Three rates are reported:  The percentage of children and adolescents on antipsychotics who received blood glucose testing  The percentage of children and adolescents on antipsychotics who received cholesterol testing  The percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing
	*Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	HEDIS	Ages 1 to 17	Annual	Members who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment
	Use of Opioids at High Dosage (HDO)	HEDIS	Ages 18 and older	Annual	For members receiving prescription opioids for ≥ 15 days during the measurement year at a high dosage (average morphine milligram equivalent dose ≥ 90 mg)
	Use of Opioids From Multiple Providers (UOP)	HEDIS	Ages 18 and older	Annual	For members receiving prescription <b>opioids</b> for ≥ 15 days during the measurement year who received opioids from multiple providers. Three rates are reported:  • Multiple Prescribers: Received prescriptions from four or more different providers  • Multiple Pharmacies: Received prescriptions from four or more different pharmacies  • Multiple Prescribers and Multiple Pharmacies: Received prescriptions from four or more different pharmacies

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
	Risk of Opioid Use (COU)	HEDIS	Ages 18 and older	Annual	<ul> <li>Members who have a new episode of opioid use that puts them at risk for continued opioid use — Two rates are reported:</li> <li>The percentage of members whose new episode of opioid use lasts at least 15 days in a 30-day period</li> <li>The percentage of members whose new episode of opioid use lasts at least 31 days in a 62-day period</li> </ul>
Utilization Measures	*Identification of Alcohol and Other Drug Services (IAD)	HEDIS	Not specified	Annual	Members with an alcohol and other drug (AOD) claim who received the following chemical dependency services during the measurement year:  Inpatient.  Intensive outpatient or partial hospitalization.  Outpatient or medication treatment.  ED.  Telehealth.  Any service.
	*Mental Health Utilization (MPT)	HEDIS	Not specified	Annual	<ul> <li>Members receiving the following mental health services during the measurement year:</li> <li>Inpatient.</li> <li>Intensive outpatient or partial hospitalization.</li> <li>Outpatient.</li> <li>ED.</li> <li>Telehealth.</li> <li>Any service.</li> </ul>
	Antibiotic Utilization (ABX)	HEDIS	Not specified	Annual	Outpatient utilization of antibiotic prescriptions during the measurement year, stratified by age and gender:  Total number of antibiotic prescriptions.  Average number of antibiotic prescriptions per member per year (PMPY).  Total days supplied for all antibiotic prescriptions.  Average days supplied per antibiotic prescription.  Total number of prescriptions for antibiotics of concern.  Average number of prescriptions PMPY for antibiotics of concern.  Percentage of antibiotics of concern for all antibiotic prescriptions.  Average number of antibiotics PMPY reported by drug class:  For selected "antibiotics of concern."  For all other antibiotics.

Clinical population	Measure	Source	Inclusion criteria	Occurrence	Description of measurement, screening, test or treatment needed
Patient experience	Getting Health Care From Specialists	CAHPS	Members who have been with the plan through the year	Annual	<ul> <li>Specialists are doctors like surgeons, heart doctors, allergy doctors, skin doctors and other doctors who specialize in one area of health care. In the last six months, did you make any appointments to see a specialist?</li> <li>In the last six months, how often did you get an appointment to see a specialist as soon as you needed?</li> <li>How many specialists have you seen in the last 6 months?</li> <li>We want to know your rating of the specialist you saw most often in the last six months. Using any number from 0 to 10, where 0 is the worst specialist possible and 10 is the best specialist possible, what number would you use to rate that specialist?</li> </ul>
	Rating of Personal Doctor	CAHPS	Members who have been with the plan through the year	Annual	<ul> <li>In the last 6 months, how many times did you visit your personal doctor to get care for yoursel f?</li> <li>In the last 6 months, how often did your personal doctor explain things in a way that was easy to understand?</li> <li>In the last 6 months, how often did your personal doctor listen carefully to you?</li> <li>In the last 6 months, how often did your personal doctor show respect for what you had to say?</li> <li>In the last 6 months, how often did your personal doctor spend enough time with you?</li> <li>In the last 6 months, did you get care from a doctor or other health provider besides your personal doctor?</li> <li>In the last 6 months, how often did your personal doctor seem informed and up to date about the care you got from these doctors or other health providers?</li> <li>Using any number from 0 to 10, where 0 is the worst health care possible and 10 is the best health care possible, what number</li> </ul>